BioCentury | Feb 20, 2021
Politics, Policy & Law

Creating access to cancer drugs in Africa

At the beginning of the 21st century, governments, philanthropies and pharmaceutical companies came together to provide Africans access to HIV medications, saving millions of lives by reducing the disparities...
BioCentury | Sep 9, 2020
Product Development

Back to School, behind the scenes: a BioCentury podcast

BioCentury’s Back to School has returned for the twenty-eighth consecutive year, prescribing biopharma’s once-in-a-generation opportunity to reboot how drug development is done in the wake of the COVID-19 pandemic. On the latest edition of the...
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

The U.S. government is taking non-conventional paths to point-of-care and pooled technologies in its push to bulk up and speed up the country’s strained COVID-19 testing capacity. In HHS’s case, the department is scrambling to...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

GSK has formally started the process of splitting its innovative R&D and consumer health businesses into two companies, while continuing to cull down its clinical pipeline. In its 4Q19 earnings Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
BioCentury | Dec 13, 2019
Product Development

Leveraging real-world data to assess the promise of CAR Ts, Dutch style

With the next set of expensive CAR T therapies poised to enter the market based on limited datasets, the Netherlands is proactively gathering the evidence it needs to make reimbursement decisions. The Dutch Health Institute...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

...hired Mark Sampson as CSO, succeeding co-founder Travis Whitfill, who will become executive director of advanced technology...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
BioCentury | Dec 21, 2018
Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
BioCentury | Dec 19, 2018
Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
BioCentury | Mar 16, 2018
Financial News

Optum names Witty CEO, launches fund

...UnitedHealth Group announced Optum Ventures' $100 million Global Fund, which will invest in "emerging and advanced technology...
Items per page:
1 - 10 of 240
BioCentury | Feb 20, 2021
Politics, Policy & Law

Creating access to cancer drugs in Africa

At the beginning of the 21st century, governments, philanthropies and pharmaceutical companies came together to provide Africans access to HIV medications, saving millions of lives by reducing the disparities...
BioCentury | Sep 9, 2020
Product Development

Back to School, behind the scenes: a BioCentury podcast

BioCentury’s Back to School has returned for the twenty-eighth consecutive year, prescribing biopharma’s once-in-a-generation opportunity to reboot how drug development is done in the wake of the COVID-19 pandemic. On the latest edition of the...
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

The U.S. government is taking non-conventional paths to point-of-care and pooled technologies in its push to bulk up and speed up the country’s strained COVID-19 testing capacity. In HHS’s case, the department is scrambling to...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

GSK has formally started the process of splitting its innovative R&D and consumer health businesses into two companies, while continuing to cull down its clinical pipeline. In its 4Q19 earnings Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
BioCentury | Dec 13, 2019
Product Development

Leveraging real-world data to assess the promise of CAR Ts, Dutch style

With the next set of expensive CAR T therapies poised to enter the market based on limited datasets, the Netherlands is proactively gathering the evidence it needs to make reimbursement decisions. The Dutch Health Institute...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

...hired Mark Sampson as CSO, succeeding co-founder Travis Whitfill, who will become executive director of advanced technology...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
BioCentury | Dec 21, 2018
Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
BioCentury | Dec 19, 2018
Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
BioCentury | Mar 16, 2018
Financial News

Optum names Witty CEO, launches fund

...UnitedHealth Group announced Optum Ventures' $100 million Global Fund, which will invest in "emerging and advanced technology...
Items per page:
1 - 10 of 240